Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.96
+4.6%
$3.01
$1.60
$16.55
$293.57M1.181.08 million shs567,348 shs
iRadimed Corporation stock logo
IRMD
iRadimed
$59.85
+0.0%
$56.82
$42.34
$63.29
$761.23M0.9144,240 shs24,015 shs
RxSight, Inc. stock logo
RXST
RxSight
$8.31
+4.5%
$14.26
$6.32
$58.23
$338.45M1.21797,932 shs2.99 million shs
SiBone stock logo
SIBN
SiBone
$18.81
+2.0%
$18.07
$11.70
$20.05
$801.38M0.93392,120 shs85,082 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
+7.08%+11.50%+17.03%+103.23%-64.37%
iRadimed Corporation stock logo
IRMD
iRadimed
+0.83%-2.81%-1.63%+19.38%+36.96%
RxSight, Inc. stock logo
RXST
RxSight
-37.84%-39.50%-48.04%-43.97%-86.05%
SiBone stock logo
SIBN
SiBone
+1.49%+0.05%-2.23%+39.17%+37.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1.0905 of 5 stars
3.61.00.00.00.00.80.0
iRadimed Corporation stock logo
IRMD
iRadimed
4.6036 of 5 stars
2.52.02.54.42.03.31.9
RxSight, Inc. stock logo
RXST
RxSight
2.3504 of 5 stars
4.01.00.00.01.51.70.6
SiBone stock logo
SIBN
SiBone
4.0332 of 5 stars
2.55.00.03.32.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56217.46% Upside
iRadimed Corporation stock logo
IRMD
iRadimed
3.00
Buy$72.0020.31% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.90
Reduce$23.90187.61% Upside
SiBone stock logo
SIBN
SiBone
3.00
Buy$22.5019.65% Upside

Current Analyst Ratings Breakdown

Latest CATX, IRMD, SIBN, and RXST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
RxSight, Inc. stock logo
RXST
RxSight
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$24.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
iRadimed Corporation stock logo
IRMD
iRadimed
$73.24M10.39$1.60 per share37.49$6.85 per share8.74
RxSight, Inc. stock logo
RXST
RxSight
$139.93M2.41N/AN/A$6.98 per share1.19
SiBone stock logo
SIBN
SiBone
$176.60M4.54N/AN/A$3.98 per share4.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)
iRadimed Corporation stock logo
IRMD
iRadimed
$19.23M$1.5538.6129.92N/A26.33%23.28%20.59%7/30/2025 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)

Latest CATX, IRMD, SIBN, and RXST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
iRadimed Corporation stock logo
IRMD
iRadimed
$0.45N/AN/AN/AN/AN/A
8/7/2025Q2 2025
RxSight, Inc. stock logo
RXST
RxSight
-$0.0363N/AN/AN/A$39.78 millionN/A
8/4/2025Q2 2025
SiBone stock logo
SIBN
SiBone
-$0.19N/AN/AN/A$48.12 millionN/A
5/7/2025Q1 2025
RxSight, Inc. stock logo
RXST
RxSight
-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million
5/5/2025Q1 2025
SiBone stock logo
SIBN
SiBone
-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
iRadimed Corporation stock logo
IRMD
iRadimed
$0.681.14%N/A43.87%1 Years
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A

Latest CATX, IRMD, SIBN, and RXST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
iRadimed Corporation stock logo
IRMD
iRadimed
quarterly$0.171.3%5/20/20255/20/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
iRadimed Corporation stock logo
IRMD
iRadimed
N/A
8.87
7.62
RxSight, Inc. stock logo
RXST
RxSight
N/A
12.68
11.65
SiBone stock logo
SIBN
SiBone
0.21
8.53
7.26

Institutional Ownership

CompanyInstitutional Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
iRadimed Corporation stock logo
IRMD
iRadimed
92.34%
RxSight, Inc. stock logo
RXST
RxSight
78.78%
SiBone stock logo
SIBN
SiBone
98.11%

Insider Ownership

CompanyInsider Ownership
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
iRadimed Corporation stock logo
IRMD
iRadimed
36.80%
RxSight, Inc. stock logo
RXST
RxSight
9.57%
SiBone stock logo
SIBN
SiBone
4.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
iRadimed Corporation stock logo
IRMD
iRadimed
11012.72 million8.04 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.64 million36.75 millionOptionable
SiBone stock logo
SIBN
SiBone
35042.62 million40.91 millionOptionable

Recent News About These Companies

SiBone (NASDAQ:SIBN) Shares Sold by Brown Advisory Inc.
Anshul Maheshwari Sells 5,005 Shares of SiBone (NASDAQ:SIBN) Stock
Michael A. Pisetsky Sells 3,127 Shares of SiBone (NASDAQ:SIBN) Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.96 +0.18 (+4.63%)
As of 02:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

iRadimed stock logo

iRadimed NASDAQ:IRMD

$59.84 +0.03 (+0.04%)
As of 02:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

RxSight stock logo

RxSight NASDAQ:RXST

$8.30 +0.35 (+4.42%)
As of 02:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

SiBone stock logo

SiBone NASDAQ:SIBN

$18.80 +0.37 (+1.98%)
As of 02:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.